HomeCompareADDXF vs PM

ADDXF vs PM: Dividend Comparison 2026

ADDXF yields 202.02% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADDXF wins by $126.48M in total portfolio value
10 years
ADDXF
ADDXF
● Live price
202.02%
Share price
$0.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$126.53M
Annual income
$64,106,411.82
Full ADDXF calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — ADDXF vs PM

📍 ADDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADDXFPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADDXF + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADDXF pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADDXF
Annual income on $10K today (after 15% tax)
$17,171.72/yr
After 10yr DRIP, annual income (after tax)
$54,490,450.05/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, ADDXF beats the other by $54,488,331.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADDXF + PM for your $10,000?

ADDXF: 50%PM: 50%
100% PM50/50100% ADDXF
Portfolio after 10yr
$63.29M
Annual income
$32,054,451.92/yr
Blended yield
50.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

ADDXF
No analyst data
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADDXF buys
0
PM buys
0
No recent congressional trades found for ADDXF or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADDXFPM
Forward yield202.02%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$126.53M$49.6K
Annual income after 10y$64,106,411.82$2,492.02
Total dividends collected$119.31M$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ADDXF vs PM ($10,000, DRIP)

YearADDXF PortfolioADDXF Income/yrPM PortfolioPM Income/yrGap
1← crossover$30,902$20,202.02$11,648$408.29+$19.3KADDXF
2$91,409$58,344.23$13,589$495.90+$77.8KADDXF
3$259,102$161,293.94$15,877$603.21+$243.2KADDXF
4$704,521$427,281.62$18,580$734.88+$685.9KADDXF
5$1,839,646$1,085,809.10$21,781$896.75+$1.82MADDXF
6$4,618,204$2,649,782.60$25,578$1,096.12+$4.59MADDXF
7$11,158,255$6,216,776.60$30,092$1,342.17+$11.13MADDXF
8$25,977,314$14,037,980.69$35,470$1,646.46+$25.94MADDXF
9$58,339,227$30,543,501.04$41,892$2,023.58+$58.30MADDXF
10$126,529,384$64,106,411.82$49,578$2,492.02+$126.48MADDXF

ADDXF vs PM: Complete Analysis 2026

ADDXFStock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Full ADDXF Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this ADDXF vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADDXF vs SCHDADDXF vs JEPIADDXF vs OADDXF vs KOADDXF vs MAINADDXF vs MOADDXF vs BTIADDXF vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.